title: The pros and cons of plasmapheresis therapy carried out on time.
authors.forename: M Jesús
authors.initials: MJ
authors.lastname: Izquierdo-Ortiz
authors.forename: Verónica
authors.initials: V
authors.lastname: Mercado-Valdivia
authors.forename: Vanesa
authors.initials: V
authors.lastname: Camarero-Temiño
authors.forename: Badawi
authors.initials: B
authors.lastname: Hijazi-Prieto
authors.forename: Isabel
authors.initials: I
authors.lastname: Saiz-Calero
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Angola-Muquel
authors.forename: Mercedes
authors.initials: M
authors.lastname: Muñoz-Merino
authors.forename: Blanca
authors.initials: B
authors.lastname: Rodríguez-Velasco
authors.forename: Pedro
authors.initials: P
authors.lastname: Abaigar-Luquin
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery / Q000628:therapy; D007678:Kidney Glomerulus / Q000503:physiopathology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010539:Permeability; D010956:Plasmapheresis / Q000009:adverse effects / Q000379:methods; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology / Q000628:therapy
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D006023:Glycoproteins